Fautrel describes a series of 13 #AOSD (Stills) pts with Pulmonary arterial HTN (cath confirmed) - seen exclusively with women, 85% and all were on DMARDs - 31% MTX, 69% IL-1i, all on steroids- 5 deaths, 3 yr Survival 74% (same as PAH) #ACR21 Abstract 1100 https://t.co/qR21MdYG3A https://t.co/WN38ifgtT6

• https://bit.ly/3qiMuvi

#ACR21 Abs#1224. ⬇️ CD39 expression on B cell predicts occurrence of anti-drug Ab in RA on RTX ⭐️13/23 pts on RTX became ADAb+. No diff in concomitant MTX usage ⭐️Baseline CD73 similar, but lower CD39 predictive of ADAb https://t.co/QzbAmXtTmZ @Rheumnow https://t.co/CLtEev69YD

• https://bit.ly/2YpkRVG

#ACR21 Abs#1225: B/L Extracell Matrix Biomarkers predict ABA response in MTX-naive, +ACPA early RA ⭐️ECM biomarkers predict SDAI remission or DAS28 w ABA+MTX vs PBO+MTX. ⭐️⬆️CTX1 biomarker predicts efficacy endpts for ABA+MTX https://t.co/7wHQefb5D4 @Rheumnow

• https://bit.ly/31wNLV2

Wnt signaling - Lorecivivint is now in phase 3 https://t.co/JSk2nPBTrI

Great talk by @saadhealth #ACR21 & interesting to compare myocarditis irAEs to inflamm arthritis irAEs: similar: - importance of confirming dx well - cautious adoption steroid-sparing Rx different: - clear benefit hard/early Rx - dx metrics aided by tech #ACR21 7S404 @RheumNow https://t.co/mFjM3ZlZaP

NORD-STAR Trial: outcomes in tx-naïve, early RA pts after 48w of csDMARDs+GC vs bDMARD (ABAtacept, CerToliZumab, or ToCiluZumab)+MTX ➡️ Superior CDAI remission rates w/ ABA+MTX & CZP+MTX but not TCZ+MTX vs csDMARD+GC ➡️Imaging progression low in all Abst#0825 #ACR21 @RheumNow https://t.co/QaFIF4WNEG